Adult patients with primary cutaneous anaplastic large cell lymphoma (C‐ALCL) or CD30‐expressing mycosis fungoides who had previously undergone systemic therapy were eligible to receive brentuximab vedotin based on the findings of the ALCANZA trial (NCT01578499).338, 339, 340, 341. This evidence concerns the gene TNFRSF8 and anaplastic large cell lymphoma.